ll Clinical and Translational Report LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Tamer Coskun, 1,3, *Shweta Urva, 1 William C
The company marketed Ozempic aggressively as a weight loss drug while downplaying serious concerns about gastroparesis, stomach paralysis, and sudden vision loss
Additionally, financial and logistical constraints can limit access to testing, particularly for marginalized or underinsured populations, where out-of-pocket costs for patch testing and allergen-free products may make testing results difficult to implement [19, 21, 40, 41]
General Findings from Studies In one clinical study involving 31 participants, researchers found that the AUC ratios for common medications like metformin, warfarin, atorvastatin, and digoxin stayed within the bioequivalence range of 0.801.25 when taken alongside semaglutide
Nohira T, Kim S, Nakai H, et al